• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

June 15, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Tychan TY027 COVID-19 initiation of phase 1 trial
Eli Lilly

Junshi Biosciences
JS016 monotherapy and combined with other antibodies COVID-19 first patient dosed in phase 1 trial
Immunic IMU-838 patients with moderate COVID-19 IND approved by the FDA
ChromaCode HDPCR SARS-CoV-2 Real-Time PCR Assay detection of SARS-CoV-2 Emergency Use Authorization (EUA) granted by the FDA
Genetron Holdings Genetron SARS-CoV-2 RNA Test detection of SARS-CoV-2 EUA granted by the FDA
Illumina Illumina COVIDSeq Test detection of SARS-CoV-2 EUA granted by the FDA
Phosphorus Diagnostics at home saliva test for COVID-19 detection of COVID-19 EUA granted by the FDA
Premier Biotech COVID-19 IgG and IgM rapid test detection of COVID-19 EUA granted by the FDA
Quidel Sofia SARS Antigen FIA rapid point-of-care test for COVID-19 EUA granted by the FDA
Other Trials and Actions
Neurana Pharmaceutical tolperisone skeletal muscle relaxant acute, painful muscle spasms without drowsiness or impact on cognititve function initiation of phase 1 study
Arcturus Therapeutics ARCT-810 Ornithine Transcarbamylase (OTC) deficiency first patient dosed in phase 1 trial
Revolution Medicines RMC-4630 plus AMG510 advanced solid tumors harboring the KRASG12C mutation first patient dosed in phase 1b trial
Precision BioSciences PBCAR269A relapsed/refractory multiple myeloma first patient dosed in phase 1/2a trial
NanOlogy IT NanoPac (submicron particle paclitaxel) non-small cell lung cancer and small cell lung cancer initiation of phase 2a trial
PDS Biotechnology PDS0101, in combination with standard of care chemoradiotherapy locally advanced cervical cancer initiation of phase 2 trial
Devonian Health Group Thykamine mild-to-moderate atopic dermatitis completion of patient enrollment in phase 2 trial
Sound Pharmaceutical SPI-1005 Meniere's Disease initiation of phase 3 trial
Clovis Oncology Rubraca (rucaparib) plus Opdivo (nivolumab) front-line maintenance treatment of newly diagnosed advanced ovarian cancer completion of patient enrollment in phase 3 trial
Bacainn Therapeutics BT051 ulcerative colitis IND approved by the FDA
Baylx BX-U001, human umbilical cord tissue mesenchymal stem cells rheumatoid arthritis IND approved by the FDA
Curis CI-8993 relapsed or refractory solid tumors IND approved by the FDA
Elixirgen Therapeutics EXG4217 telomere biology disorders with bone marrow failure IND approved by the FDA
Sapience Therapeutics ST101 adults with unresectable and metastatic solid tumors IND approved by the FDA
AlgoTherapeutix ATX01 (proprietary topical amitriptyline) erythromelalgia Orphan Drug designation granted by the FDA
MacroGenics margetuximab HER2-positive gastric cancer or gastroesophageal junction cancer Orphan Drug designation granted by the FDA
Polyneuron Pharmaceutical PN 1007 (PPSGG) anti-MAG neuropathy Orphan Drug designation granted by the FDA
TVAX Biomedical vaccine-enhanced adoptive T-cell therapy (VACT) glioblastoma multiforme Fast Track designation granted by the FDA
Insmed brensocatib (INS1007) non-cystic fibrosis bronchiectasis Breakthrough Therapy designation granted by the FDA
Rezolute RZ358 congenital hyperinsulinism Rare Pediatric Disease designation granted by the FDA
Bristol-Myers Squibb Opdivo (nivolumab) patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy approved by the FDA
Merck Recarbio hospital-acquired and ventilator-associated pneumonia caused by gram negative bacteria approved by the FDA for expanded indication

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing